Infections associated with bendamustine and anti-CD20 antibody in untreated follicular lymphoma: a real-world study.

IF 0.9 Q4 HEMATOLOGY Journal of Clinical and Experimental Hematopathology Pub Date : 2023-09-28 Epub Date: 2023-07-28 DOI:10.3960/jslrt.23015

Masuho Saburi, Kazuki Okuhiro, Natsumi Yoshida, Takami Haruyama, Yui Moroga, Yuka Yanai, Kazuhito Itani, Kuniko Takano, Shuhei Honda, Keiji Ono, Manami Iwanaga, Hitohiro Sasaki, Miyuki Abe, Kazuhiro Kohno, Toshiyuki Nakayama, Eiichi Ohtsuka, Masao Ogata

{"title":"Infections associated with bendamustine and anti-CD20 antibody in untreated follicular lymphoma: a real-world study.","authors":"Masuho Saburi, Kazuki Okuhiro, Natsumi Yoshida, Takami Haruyama, Yui Moroga, Yuka Yanai, Kazuhito Itani, Kuniko Takano, Shuhei Honda, Keiji Ono, Manami Iwanaga, Hitohiro Sasaki, Miyuki Abe, Kazuhiro Kohno, Toshiyuki Nakayama, Eiichi Ohtsuka, Masao Ogata","doi":"10.3960/jslrt.23015","DOIUrl":null,"url":null,"abstract":"), and PFS were compared between the BR and GB groups. Tumor volume was determined according to the Groupe d’Étude des Lymphomes Folliculaires (GELF) criteria, and response was determined according to the International Workshop to standardize response criteria for NHL, 9 using computed tomography (CT) or 18 F-fluorodeoxyglucose positron emission tomography/CT (FDG-PET/CT). Adverse events including febrile neutropenia, sepsis, pneumonia, herpes zoster, and cytomegalovirus (CMV) infection, were evaluated by CTCAE Ver5.0. Survival was analyzed starting from the date of treatment initiation. PFS was defined as the period from treatment to dis - ease progression, relapse, or death. The cumulative incidence of CMV infection was analyzed using Gray’s test, and the competing events were deaths due to causes other than infection. All statistical analyses were performed with EZR software. 10 This study was approved by the ethics review board of Oita Prefectural Hospital, and by the ethics review board of each collaborating research institution. Patients’ informed consent was obtained in the form of opt-out on a","PeriodicalId":45936,"journal":{"name":"Journal of Clinical and Experimental Hematopathology","volume":" ","pages":"197-200"},"PeriodicalIF":0.9000,"publicationDate":"2023-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628822/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical and Experimental Hematopathology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3960/jslrt.23015","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/7/28 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

), and PFS were compared between the BR and GB groups. Tumor volume was determined according to the Groupe d’Étude des Lymphomes Folliculaires (GELF) criteria, and response was determined according to the International Workshop to standardize response criteria for NHL, 9 using computed tomography (CT) or 18 F-fluorodeoxyglucose positron emission tomography/CT (FDG-PET/CT). Adverse events including febrile neutropenia, sepsis, pneumonia, herpes zoster, and cytomegalovirus (CMV) infection, were evaluated by CTCAE Ver5.0. Survival was analyzed starting from the date of treatment initiation. PFS was defined as the period from treatment to dis - ease progression, relapse, or death. The cumulative incidence of CMV infection was analyzed using Gray’s test, and the competing events were deaths due to causes other than infection. All statistical analyses were performed with EZR software. 10 This study was approved by the ethics review board of Oita Prefectural Hospital, and by the ethics review board of each collaborating research institution. Patients’ informed consent was obtained in the form of opt-out on a

查看原文